Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

bluebird bio

On Oct. 19, I reviewed three of the 10 companies a Jeffries health care analyst thinks are most likely to be acquired by members of Big Pharma. Now let's look at numbers four through six on the list Jeffries' Jaret Holtz provided to FierceBiotech.

Bristol-Myers' Acquisition of Bluebird Seems to Make Sense

An analyst at Guggenheim Securities turned bullish on pharma giant Bristol-Myers Squibb Co (NYSE: BMY) Monday, basing their optimism on a revival in sales of its flagship immuno-oncology drug Opdivo. The Bristol-Myers Squibb Analyst:  Analyst Seamus Fernandez upgraded Bristol-Myers Squibb shares from Neutral to Buy with a new $70 price target.

Bristol-Myers Squibb Analyst Sees Multiple Expansion Story, Limited Near-Term Downside Risk

GlaxoSmithKline

Merck

Seagen

Vertex Pharmaceuticals

Let us take a look at some drug/biotech stocks including Glaxo (GSK) and Merck (MRK) that are poised to beat on earnings for the third quarter.

5 Big Pharma/Biotech Stocks Set to Trump Q3 Earnings Estimates

The CHMP passes a favorable opinion for the approval of Bristol-Myers' (BMY) Opdivo to address advanced/ metastatic esophageal squamous cell carcinoma in the EU.

Bristol-Myers' (BMY) Opdivo Gets Positive CHMP View for ESCC

Exelixis

Bristol Myers Squibb and Exelixis announced Monday that the FDA had granted priority review for their combined treatment for a form of advanced kidney cancer; and BMY stock, EXEL stock rose. The post Bristol Myers Squibb, Exelixis Granted FDA Priority Review For Kidney Cancer Treatment appeared first on Investor's Business Daily.

Bristol Myers Squibb, Exelixis Granted FDA Priority Review For Kidney Cancer Treatment

PRINCETON, N.J. & ALAMEDA, Calif.--(BUSINESS WIRE)---- $BMY #BMS--US FDA Accepts for Priority Review Applications for OPDIVO® in Combination with CABOMETYX® in Advanced Renal Cell Carcinoma

U.S. Food and Drug Administration Accepts for Priority Review Applications for OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Advanced Renal Cell Carcinoma

Freshpet

Alphabet

NextEra Energy

Stock market crashes and corrections are inevitable -- but they do open the door to some incredible bargains for investors.

4 Perfect Stocks to Buy if the Stock Market Crashes

Amgen

Here's how these two big drugmakers stack up against each other in several key categories.

Better Buy: Amgen vs. Bristol Myers Squibb

This blue-chip pharma stock is a bargain for long-term investors.

Why I Think Bristol Myers Squibb Is Too Cheap to Miss

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ATTRACTION3--BMS Receives Positive CHMP Opinion Recommending Opdivo as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal....

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

AbbVie

Johnson & Johnson

UnitedHealth Group

To say that hedge fund and mutual fund managers tend to follow the herd is an incredible understatement and always has been.

Wall Street Fund Managers Love These 5 Large Cap Health Care Stocks

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--BMS Presents Positive Late-Breaking Data from Phase 3 True North Trial Evaluating Zeposia in Adult Patients w/ Moderate to Severe Ulcerative Colitis

Bristol Myers Squibb Presents Positive Late-Breaking Data from Phase 3 True North Trial Evaluating Zeposia (ozanimod) in Adult Patients with Moderate to Severe Ulcerative Colitis

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of MyoKardia, Inc. (NasdaqGS: MYOK) to Bristol Myers Squibb (NYSE: BMY). Under the terms of the proposed transaction, shareholders of MyoKardia will receive only $225.00 in cash for each share of MyoKardia that they own. KSF is seeking to determine whether this consideration and the process that led to it are ade

MYOKARDIA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of MyoKardia, Inc. - MYOK

Sheep of Wall Street posted pictures of a supposed plant visit by FDA inspectors that's crucial to the Bristol-Myers/Celgene milestone.

Bristol-Myers Squibb: FDA Inspection Secured

Bristol Myers' (BMY) shares gain as the phase III study evaluating Opdivo plus chemotherapy meets primary endpoint for the indication of NSCLC.

Bristol Myers (BMY) Gains on Positive Opdivo Data in NSCLC

Bristol Myers Squibb posted positive Phase 3 data for one of its top drugs, Opdivo, for use in treating patients with certain types of non-small cell lung cancer, and BMY stock rose early. The post Bristol Myers Shares Up On Positive Data For Lung Cancer Treatment appeared first on Investor's Business Daily.

Bristol Myers Shares Up On Positive Data For Lung Cancer Treatment

MyoKardia

Cardiovascular drugs have been unsuccessful investments in recent years, but this one makes sense.

Here's Why Bristol Myers Offered MyoKardia $13.1 Billion

Shares of Bristol Myers Squibb Co. BMY, -2.46% were up 1.1% in premarket trading on Wednesday after the drug maker said its immuno-oncology therapy Opdivo had showed promising results treating patients with resectable non-small cell lung cancer in combination with chemotherapy. The randomized, open-label, Phase 3 study enrolled 358 patients, and it found that patients who took a combination of the two drugs before surgery were more likely to demonstrate "no evidence of cancer cells" than those who took chemotherapy alone.

Bristol Myers Squibb's stock gains on new Opdivo data in lung cancer

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Opdivo Plus Chemotherapy Shows Statistically Significant Improvement in Pathologic Complete Response as Neoadjuvant Treatment of....

Opdivo (nivolumab) Plus Chemotherapy Shows Statistically Significant Improvement in Pathologic Complete Response as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial

Myokardia Inc (NASDAQ: MYOK) announced Monday a definitive agreement to be bought by Bristol-Myers Squibb Co (NYSE: BMY). The Myokardia Analysts: Wedbush analyst David Nierengarten downgraded Myokardia from Outperform to Neutral and raised the price target from $127 to $225.

Myokardia Analysts See Mavacamten As Blockbuster Opportunity For Bristol-Myers Squibb

After a relatively dull first half of 2020, M&A activity in the drug and biotech sector seems to be picking up in the second half of 2020.

Pharma M&As Pick Up as Bristol-Myers Offers to Buy MyoKardia

"MyoKardia is an important company because they developed a really interesting approach to the treatment of cardiovascular disease," Bristol-Myers Squibb CEO Giovanni Caforio said.

Bristol-Myers gets 'potentially revolutionary medicine' in MyoKardia deal, CEO says

MyoKardia's major, $13.1 billon deal with fellow pharmaceutical company Bristol Myers Squibb sent MYOK stock soaring on Monday. The post M&A News: MyoKardia (MYOK) Stock Soars on Bristol Myers Squibb Deal appeared first on InvestorPlace.

M&A News: MyoKardia (MYOK) Stock Soars on Bristol Myers Squibb Deal

The transaction will give Bristol Myers Squibb a potential first-in-class cardiovascular drug with blockbuster expectations.

Bristol Myers Squibb Begins a $13.1 Billion Purchase of MyoKardia

Bristol Myers' (BMY) Opdivo in combination with Yervoy gets an FDA approval for malignant pleural mesothelioma.

News for Bristol-Myers Stock (BMY)